OncoSil Medical Limited

OSL

AU000000OSL3

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-04-24 am EDT			5-day change	1st Jan Change
0.005 ^AUD	+25.00%		-28.57%	-44.44%

Apr. 18	OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial	MT
Apr. 16	OncoSil Medical Treats First Commercial Patient in Turkey with Implantable Pancreatic Cancer Device	MT

OncoSil Medical Limited Announces Change of Registered Office and Principal Place of Business

February 28, 2021 at 05:10 pm EST

OncoSil Medical Limited announced that as of immediate effect its registered office and principal place of business will change to: Suite 503, Level 5, 15 Blue Street, North Sydney NSW 2060, Australia.

Latest news about OncoSil Medical Limited

OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial	Apr. 17	MT
OncoSil Medical Treats First Commercial Patient in Turkey with Implantable Pancreatic Cancer Device	Apr. 15	MT
OncoSil Medical Treats First UK Patient for Pancreatic Cancer Study	Apr. 11	MT
OncoSil Medical Obtains Device Reimbursement Approval in UK	Apr. 08	MT
First Austria-Based Patients Treated Using OncoSil Pancreatic Cancer Device	Apr. 04	MT
Oncosil Medical Issues Non-Renounceable Entitlement Offer Prospectus	Mar. 24	MT
Oncosil Medical to Raise Over AU$7 Million via Placement, Entitlement Offer	Mar. 19	MT
OncoSil Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Australian Shares End Eight-Day Winning Streak as Early US Fed Rate Cut Hopes Fade	Feb. 01	MT
OncoSil Device Included in German Funding Program Negotiations; Shares Jump 14%	Jan. 31	MT
OncoSil Strikes Exclusive Distribution Deal For Turkish Market; Shares Jump 14%	Jan. 31	MT
OncoSil Medical Receives AU$1.1 Million R&D Tax Rebate	Dec. 15	MT
First Patient Treated in OncoSil Medical's Pancreatic Cancer Drug Trial	Nov. 28	MT
Oncosil Medical Limited Elects Gabrielle Liberatore as Director	Nov. 28	CI
Australian Shares Rise on Expectations of Easing October CPI	Nov. 24	MT
OncoSil Medical Secures Insurer Clearance for Pancreatic Cancer Device in Israel	Nov. 23	MT
OncoSil Medical Limited Announces Retirement of Brian Leedman from the Board	23-09-18	CI
OncoSil Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
Oncosil Medical Limited Announces Change of Principal Place of Business	23-08-16	CI
OncoSil Medical Limited Appoints Doug Cubbin as Director	23-08-09	CI
Oncosil Medical Appoints Incoming Chair	23-08-07	MT
OncoSil Appoints Gabriel Liberatore to the Board	23-07-14	CI
Genetic Signatures Appoints CFO/COO	23-06-15	MT
OncoSil Medical Secures Ethics Approval for Pancreatic Cancer Trial	23-06-05	MT
Oncosil Medical Appoints CFO	23-06-01	MT

Chart OncoSil Medical Limited

Duration

Period

More charts

Company Profile

OncoSil Medical Ltd is an Australia-based medical device company seeking to advance radiation for cancer patients. The Company is focused on the development and commercialization of its lead product candidate, OncoSil localized radiation therapy, for the treatment of pancreatic and distal cholangiocarcinoma. OncoSil is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patientâs pancreatic tumors through an endoscopic ultrasound. OncoSil is a single-use brachytherapy device that has received breakthrough device designation in the European Union, the United Kingdom, and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy. OncoSil comprises phosphorous-32 microparticles suspended in a specially formulated diluent. OncoSil is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ONCOSIL MEDICAL LIMITED	-44.44%	7.32M
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.24%	358B
MERCK & CO., INC.	+19.29%	322B
ABBVIE INC.	+7.78%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-11.65%	149B
AMGEN INC.	-6.19%	146B

Other Pharmaceuticals